Abbott Q1 FY2026 Earnings Insight-Exact Sciences Deal Closes Amid Strong MedTech Performance, While Respiratory Testing Drags

Abbott Laboratories (ABT) Q1 FY2026 Earnings: Exact Sciences Deal Closes Amid Strong MedTech Performance, While Respiratory Testing Drags

Abbott Laboratories kicked off its fiscal 2026 with a first quarter that landed right on target. The company reported adjusted EPS of $1.15, which met Wall Street estimates and represented a solid 6% jump compared to the same period last year. Overall comparable sales grew by 3.7%.

But beneath the headline numbers, the quarter was a tale of two different realities. On one side, Abbott’s core medical device and pharmaceutical businesses fired on all cylinders, proving the company’s underlying growth engine is incredibly healthy. On the other side, a shockingly weak winter respiratory virus season pulled down diagnostic revenues much harder than management originally modeled.

The biggest news of the quarter, however, was strategic rather than purely financial. Abbott officially closed its massive acquisition of Exact Sciences in late March. This move aggressively shifts the company’s diagnostic footprint away from infectious diseases and into the high-growth world of oncology.

Overall, the tone from management was highly confident. They view the current headwinds as temporary and see a clear path to faster growth in the back half of the year. Investors looking at Abbott right now are seeing a company going through a clean transition, absorbing a major acquisition, and preparing for a heavy wave of new product launches.

Abbott Investor Relations website

Key Financial Highlights

The first quarter financials showed resilience despite some clear sector-specific hurdles. Here is a look at the key numbers:

• Earnings Per Share (EPS): Adjusted EPS came in at $1.15, up 6% year-over-year. This was right in line with the company’s internal guidance.

• Revenue Growth: Comparable sales increased by 3.7%. This metric includes the historical baseline of Exact Sciences to give investors a cleaner look at the combined company’s real growth rate.

• Currency Impact: Foreign exchange was a helpful tailwind. A weaker U.S. dollar added a favorable 4% boost to first-quarter sales.

• Gross Margins: Adjusted gross margin settled at 56.3% of total sales.

• Operating Expenses: Adjusted R&D spending hit 6.7% of sales, while adjusted SG&A landed at 29.3%.

Operational and Segment Breakdown

Abbott is a highly diversified healthcare giant, and that diversity saved the quarter. Weakness in one area was easily offset by strength in others.

Medical Devices

This was the star of the show. The medical device segment grew 8.5%, driven almost entirely by the cardiovascular business.

• Electrophysiology (EP): Sales jumped 13%. This was fueled by the much-anticipated launches of two new pulsed field ablation (PFA) catheters. The Volt PFA catheter drove 14% growth in the U.S., while the TactiFlex Duo pushed European sales into the mid-teens.

• Rhythm Management: This unit posted 13% growth, marking its third straight quarter of double-digit gains. Management noted they are significantly outperforming the broader market here.

• Heart Failure: Grew a very strong 12%, backed by a solid portfolio of heart assist devices.

• Diabetes Care (CGM): The continuous glucose monitoring business, anchored by the FreeStyle Libre, hit $2 billion in sales and grew 7.5%. While this looks like a slowdown, management explained it was caused by a delayed international tender renewal and a tough year-over-year comparison related to inventory restocking in early 2025. They expect this segment to bounce back to double-digit growth next quarter.

• Structural Heart: Growth was softer here. Management admitted to facing intense competitive pressure in the mitral valve space and cited a need for better commercial execution in the U.S.

Diagnostics

The diagnostics group is going through a massive structural shift.

• Core Lab Diagnostics: Sales grew 2% overall, but underlying demand was better. Growth hit 3% across the U.S., Europe, and Latin America. Management noted that test volumes are increasing sequentially.

• Rapid and Molecular: This was the weak spot. Sales fell 10% simply because the flu and RSV season was incredibly mild compared to last year. People did not get sick as much, so they did not buy tests.

• Cancer Diagnostics: The new bright spot following the Exact Sciences deal. Sales surged 13%, driven by mid-teens growth for the Cologuard test and high-teens growth in overseas markets.

Nutrition

Nutrition sales came in slightly ahead of expectations. Last year, Abbott realized it was losing market share because its prices were too high. In late 2025, they slashed prices on key products like Ensure to win back customers. The strategy is working. Volume growth is finally returning, though it will take a few more quarters for the financial numbers to fully reflect the turnaround.

Established Pharmaceuticals (EPD)

This segment is often overlooked but it remains a quiet powerhouse. Sales grew 9%, with double-digit growth popping up across Latin America and the Asia-Pacific regions. The business is benefiting from long-term demographic trends and an expanding portfolio of biosimilar drugs.

Johnson & Johnson-JNJ-Q1 FY-26 Earnings Call Note-pushing worldwide revenue to $24.1 billion

Portfolio Strategy: The Strength of Diversification

During the call, CEO Robert Ford laid out a clear philosophy on how Abbott manages its massive business footprint. The company is built to avoid relying too heavily on one or two hit products.

Instead, Abbott balances different innovation cycles, payer types, and geographic footprints. When one unit struggles—like the rapid diagnostics group did this quarter due to a warm winter—other groups like pharmaceuticals and medical devices pick up the slack.

Management also made it clear that they constantly evaluate their portfolio at the board level to make sure every unit is creating value. However, they refuse to make long-term, knee-jerk decisions based on short-term problems. This means they are committed to fixing the nutrition business rather than spinning it off or selling it when times get tough.

Deep Dive into the MedTech Pipeline

Abbott is funneling cash into some major technological leaps. They are preparing to enroll patients in clinical trials in the second half of the year for several highly anticipated products. This includes technologies gained from recent acquisitions.

Key pipeline highlights include:

• A new balloon expandable TAVR valve.

• A leadless conduction system pacing device using their popular AVEIR technology.

• A mitral replacement valve developed through their acquisition of Cephea Valve Technologies.

• A peripheral IVL device stemming from the CSI acquisition.

• A wearable continuous lactate monitoring sensor designed to track patients for sepsis after they leave the hospital.

Management Commentary and Strategic Direction

CEO Robert Ford sounded incredibly optimistic about the back half of the year. His commentary focused heavily on execution and the long-term pipeline rather than short-term noise.

“We remain very confident in our expectation for an acceleration in growth in the second half of the year. We know what the drivers are. We know where the accelerations are. We know the areas that we need to improve our execution on, and we are just laser-focused on executing on them.”

Ford made it clear that Abbott is not going to rely on a sudden return of respiratory virus testing to hit its numbers. Instead, he expects the heavy lifting to be done by the new electrophysiology products, the continued recovery of the nutrition business, and the integration of Exact Sciences. He was also highly defensive of the diabetes business, pushing back against Wall Street worries that the CGM market is getting saturated.

Guidance and Outlook

Management reaffirmed their full-year 2026 sales growth guidance of 6.5%-7.5%. They are now calculating this on a comparable basis that includes Exact Sciences in both the current and prior-year numbers to give a true apples-to-apples view.

On the profit side, Abbott adjusted its full-year EPS guidance downward. The new midpoint is $5.48, down from the previous $5.68. However, this was completely expected. The $0.20 drop is entirely due to the dilution caused by financing the Exact Sciences deal.

For the upcoming second quarter, Abbott expects adjusted EPS to land between $1.25 and $1.31. Currency exchange is expected to have a neutral impact in Q2, but should add about 1% to the full-year reported sales.

This guidance looks slightly conservative. By refusing to factor in a potential bounce-back in winter respiratory testing later this year, management has left themselves room to beat estimates if cold and flu season returns to normal levels.

Positives to Watch

• The Exact Sciences Integration: The deal adds $3 billion in high-growth revenue. Cologuard is heavily under-penetrated. A massive 25% of tests are now recurring rescreens, creating a highly sticky revenue base.

• Electrophysiology Acceleration: The Volt and TactiFlex catheters are just entering the market. Early feedback highlights faster procedures and better patient outcomes. Management expects this business to grow faster than the mid-to-high teens market rate by year-end.

• CGM Market Expansion: Despite short-term noise, the total addressable market for glucose monitors is staggering. Management estimates 70 to 80 million people globally need a CGM, but only 10 to 12 million use one today. Upcoming Medicare coverage for Type 2 non-insulin patients will unlock nearly 10 million new potential users in the U.S. alone.

Risks and Concerns

• Structural Heart Stumbles: Abbott is losing ground to competitors in the U.S. mitral valve market. Management openly admitted they need to execute better here. While international sales remain strong, the U.S. commercial team has a lot to prove in the coming quarters.

• Respiratory Testing Volatility: The rapid diagnostics business is completely at the mercy of Mother Nature. If next winter is as mild as this past one, this segment will continue to drag on total revenue.

• Nutrition Margin Pressures: Cutting prices to regain volume is a proven strategy, but it squeezes profit margins. Investors will need to watch closely to ensure the volume gains are actually worth the price cuts.

Capital Allocation

The immediate priority for capital is digesting the Exact Sciences deal. Abbott spent heavily to acquire the cancer testing giant, and they absorbed some early financing costs in Q1 to get the deal done.

Looking inward, Abbott is aggressively funding its clinical trial pipeline. This shows a massive commitment to organic R&D rather than just relying heavily on buying growth.

Broader Challenges

• China Value-Based Procurement (VBP): The heavy price cuts mandated by the Chinese government have hammered Abbott’s core lab business over the past year. The good news? Sales in China were finally flat in Q1, signaling that the worst of the VBP pain is likely in the rearview mirror.

• Geopolitical Supply Chain Stress: Conflicts in the Middle East have disrupted shipping lanes. While Abbott has not seen a drop in actual consumer demand, the company has had to scramble to secure freight space and stockpile inventory in local warehouses to prevent backorders.

Analyst Q&A Insights

The Q&A session was revealing. Analysts pressed hard on organic growth concerns, the health of the diabetes market, and the new direction following the Exact Sciences acquisition. Here is a breakdown of the most important exchanges.

• Question: Can you explain your guidance philosophy and if you have de-risked the outlook for any unforeseen downsides?
  Answer: Management explained they chose to be conservative regarding the upcoming flu season. They saw a weak season in Q1 and decided not to assume a strong recovery in Q4, even though they have the manufacturing capacity ready just in case. The rest of the business remains fully on track.
  Our take: This is a smart setup. By completely stripping out any hope for a respiratory testing bounce, management has lowered the bar and created an easy path for a beat-and-raise later in the year if the flu season is even slightly worse than last year.

• Question: If we back out the Exact Sciences deal, does the core organic growth rate look like it is decelerating compared to earlier guidance?
  Answer: Ford pushed back on this line of thinking. He stated that rolling Exact Sciences into the comparable numbers is the most transparent way to model the “new Abbott.” He reiterated that core medtech is growing in the low double digits and pharma is growing above 7%.
  Our take: Ford dodged the exact math a bit here. It is true that some legacy parts of the business are slowing, but he wants the market to value the company based on its new, upgraded portfolio rather than lingering on old baselines.

• Question: Prescription data for U.S. continuous glucose monitors looks weak. Is the market getting saturated?
  Answer: Ford strongly argued that looking only at weekly prescription data is myopic. He pointed out a massive global market of 70 to 80 million potential patients, with only a fraction currently using the tech.
  Our take: Ford sounded slightly frustrated but highly confident. His point about the total addressable market being a $30 to $35 billion opportunity is a strong reminder not to overreact to a few weeks of sluggish pharmacy data.

• Question: What is the timeline for new diabetes products and expanding Type 2 coverage?
  Answer: Management expects proposed coverage for Type 2 non-insulin users soon, which will unlock nearly 10 million patients. They are also on track for a second-half approval of their dual analyte system (glucose plus ketones) and are actively working on the Libre 5.
  Our take: Abbott is keeping its foot on the gas. The dual ketone sensor is a major leap forward, especially for the 5 million SGLT2 drug users, and keeps them ahead of the innovation curve.

• Question: How do you plan to sustain the mid-teens growth of Cologuard now that Exact Sciences is under the Abbott umbrella?
  Answer: The focus is on three things: expanding the patient base (potentially lowering the screening age from 45 to 40), increasing international sales where the market is untouched, and leaning into rescreens. Currently, 25% of tests are returning patients.
  Our take: The rescreening data is the golden ticket. It turns a one-off diagnostic test into a recurring subscription-like revenue model. Abbott’s global distribution network should also supercharge Exact’s international growth.

• Question: What is happening in the structural heart business, specifically with competitive pressures?
  Answer: Abbott moved its left atrial appendage closure (LAAC) business into the electrophysiology segment to help both units focus. Ford admitted that competitive intensity in the mitral space is high and the U.S. commercial team needs to execute better. Still, he expects high single-digit growth for the year.
  Our take: This was a rare moment of vulnerability. Ford basically put his U.S. structural heart sales team on notice. When a CEO says execution needs to improve on a public call, internal changes are likely already happening behind the scenes.

• Question: Can you provide more color on the volume recovery in the nutrition business?
  Answer: The targeted price cuts implemented late last year are working. Volume growth is picking up, specifically with brands like Ensure in the U.S. Management tracks this weekly and is happy with the progress, though more work is needed to expand retail distribution.
  Our take: The strategy is sound. In the consumer goods space, you cannot afford to lose shelf space. Taking a temporary margin hit to win back volume is exactly what they needed to do.

• Question: How are you thinking about ongoing portfolio management and value creation, especially with struggling segments like Nutrition?
  Answer: The company constantly evaluates its portfolio at the board level to see if markets remain attractive. However, Ford stressed they will never make long-term strategic decisions to sell or spin off a business based solely on near-term challenges.
  Our take: This shuts down any rumors that Abbott might spin off or sell the Nutrition unit. They believe the diversity of their products, geographies, and payers is a massive strength that helps them weather storms.

• Question: Are macro issues like the Middle East conflict affecting oil, resin costs, or patient volumes?
  Answer: There is no impact on patient demand or major material costs yet. The only real issue has been securing freight and shipping lanes to get products into the region. Abbott has increased local warehouse inventory to prevent shortages.
  Our take: The company is flexing its operational muscles. Having dedicated gross-margin teams working daily to navigate supply chain shocks shows why massive healthcare conglomerates tend to be safe havens during geopolitical stress.

• Question: Can you share early feedback on the Volt PFA catheter launch?
  Answer: The limited market release is going incredibly well. Doctors love the conscious sedation feature and the speed of the procedure. Ford expects Abbott to outgrow the broader EP market by the end of the year.
  Our take: Abbott was late to the PFA party, but they built a better mousetrap. If they can truly deliver better patient outcomes alongside procedural speed, they will claw back any market share they lost while waiting for approval.

• Question: How is the Core Lab diagnostics business performing globally, especially regarding the VBP headwinds in China?
  Answer: China sales were flat, marking a major improvement after quarters of 15% to 30% declines. The U.S. market is incredibly strong, with contract renewal rates above 90% and new business win rates over 55%.
  Our take: The bleeding in China has stopped. With the U.S. team practically printing money through massive contract win rates, the Core Lab division is set up for a very profitable year.

Key Takeaway

Abbott’s Q1 FY2026 was exactly what it needed to be: stable. By closing the Exact Sciences deal, management has fundamentally upgraded the company’s long-term growth profile. While the U.S. structural heart team needs to get its act together and the nutrition segment is still healing, the sheer dominance of the core medical device business covers up those minor bruises. By setting conservative guidance around respiratory testing, Abbott has given itself a wide runway to deliver upside surprises as the year progresses.